Critical insight at the speed of light.
Avalyra Biophotonics is a next-generation MedTech company advancing a new standard of care. Our non-invasive, high-fidelity monitoring of internal physiological changes means actionable insight when it’s needed most.
Our Mission: provide clinicians and care teams with the clarity they need in real time – transforming how critical care decisions are made.
Avalyra is creating health technology platforms combining advanced optical sensing, intelligent signal processing, edge computing, and cloud-enabled dashboards to track internal fluid dynamics and more – without the need for invasive lines, blood draws, or bulky machines.
At the core of Avalyra’s technology is a photonics-driven sensor system designed to detect subtle changes in vascular volume, plasma levels, and hematocrit with unprecedented sensitivity.
Built for speed, scale, and integration, the platform is hardware-agnostic and designed to evolve with clinical needs—from outpatient dialysis to battlefield trauma care.
A MedTech Platform Being Built for Critical Care Settings, Remote and Telehealth Monitoring, and Management of Chronic Conditions.
Avalyra’s platform is being designed to support multiple high-impact clinical applications:
Dialysis Optimization & Management
Preparing to usher in a new standard of care in dialysis management, enabling personalized fluid management leading to a reduction in complications and hospitalizations due to treatment.
Maternal Hemorrhage Detection
On path to address the second leading cause of maternal mortality worldwide with real-time monitoring to detect internal hemorrhage whenever it happens, including the postpartum months following a pregnancy.
Trauma & Defense
Early internal hemorrhage detection for battlefield triage, en route care, and remote deployments - empowering faster, smarter interventions.
Our Approach to Technology Development
Avalyra is building for scale and speed through a capital-efficient, streamlined approach. By leaning into strategic partnerships and a technology licensing model, our mission is to deliver life-saving innovations to market as rapidly as possible.
Our current status reflects a de-risked, innovation-ready platform:
• Clinically validated device technology
• IRB-approved clinical trials scheduled for Dialysis and Internal Hemorrhage (2025)
• DoD SBIR-backed technology with a Phase III contract path
• SAM.gov-registered and qualified Federal Contractor
• Technology Readiness Level (TRL) 5, positioned for commercial development